藥明康德(603259.SH)一季度淨利潤升394.92%至15億元
格隆匯 4 月 29日丨藥明康德(603259.SH)發佈2021年第一季度報吿,實現營業收入49.50億元,同比增長55.31%;歸屬於上市公司股東的淨利潤15億元,同比增長394.92%;歸屬於上市公司股東的扣除非經常性損益的淨利潤8.30億元,同比增長120.92%;基本每股收益0.62元。
報吿期歸屬於上市公司股東的淨利潤同比增長394.92%。在公司主營業務強勁增長的同時,報吿期內投資收益及公允價值變動收益分別實現人民幣48377.29萬元以及人民幣21180.8萬元,合計較上年同期增長人民幣84192.5萬元。主要包括:公司所投資的部分上市股份市場價值提升,另外報吿期內兩家生物製藥與技術公司順利在美國納斯達克證券交易所上市,其市場價值大幅上漲;同時,公司所投資的部分未上市醫療科技企業在報吿期內完成新輪融資,其企業價值提升。該部分股權投資收益以及非流動金融資產的公允價值變動收益影響2021年第一季度利潤為人民幣106253.42萬元(上年同期該部分影響為淨損失人民幣9400.99萬元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.